How Has the Advanced Therapy Medicinal Products Contract Development And Manufacturing Organization (CDMO) Market Evolved Historically and What is its Current Size?
The advanced therapy medicinal products contract development and manufacturing organization (cdmo) market has seen considerable growth due to a variety of factors.
• The advanced therapy medicinal products contract development and manufacturing organization (CDMO) market is expected to grow from $5.31 billion in 2024 to $6.22 billion in 2025 at a CAGR of 17.0%.
The market growth is driven by an increase in ATMP clinical trials, heightened awareness among researchers about advanced therapy benefits, more ATMP CDMOs, efforts to develop new therapies, and supportive government policies.
What Is The Projected Growth Of The Advanced Therapy Medicinal Products Contract Development And Manufacturing Organization (CDMO) Market Size In The Coming Years?
The advanced therapy medicinal products contract development and manufacturing organization (cdmo) market is expected to maintain its strong growth trajectory in upcoming years.
• The advanced therapy medicinal products (ATMP) contract development and manufacturing organization (CDMO) market is forecast to reach $11.53 billion by 2029, growing at a CAGR of 16.7%.
Growth is driven by higher investments in CDMOs, the rise of cell and gene therapy, increasing pharmaceutical R&D spending, and more clinical trials for ATMPs. Key trends include advancements in AAV biomanufacturing, expansion in gene therapy manufacturing, technological innovations in cell therapies, and integration of CRISPR and next-gen sequencing.
What Are the Critical Driver Fuelling The Advanced Therapy Medicinal Products Contract Development And Manufacturing Organization (CDMO) Market's Growth?
The rising number of clinical trials is anticipated to drive the growth of the advanced therapy medicinal products CDMO market. Clinical trials, aimed at evaluating the safety and efficacy of medical treatments, are increasing due to a rising demand for innovative therapies and a growing global disease burden. As the use of advanced therapy medicinal products rises, the demand for contract development and manufacturing organization (CDMO) services also increases. For example, in November 2023, the Association of the British Pharmaceutical Industry reported a 4.3% increase in the number of clinical trials initiated in the UK from 394 in 2021 to 411 in 2022. This increase in clinical trials is contributing to the growth of the advanced therapy medicinal products CDMO market.
What Are The Principal Market Segments In The Global Advanced Therapy Medicinal Products Contract Development And Manufacturing Organization (CDMO) Industry?
The advanced therapy medicinal products contract development and manufacturing organization (CDMO) market covered in this report is segmented –
1) By Product: Gene Therapy, Cell Therapy, Tissue Engineered
2) By Phase: Phase I, Phase II, Phase III, Phase IV
3) By Indication: Oncology, Cardiology, Central Nervous System And Musculoskeletal, Infectious Disease, Dermatology, Endocrine, Metabolic, Genetic, Immunology And Inflammation, Ophthalmology, Hematology
Subsegments:
1) By Gene Therapy: Viral Vectors, Non-Viral Vectors, Dna Or Rna-Based Products
2) By Cell Therapy: Autologous Cell Therapy, Allogeneic Cell Therapy, Stem Cell Therapy
3) By Tissue Engineered: Skin Substitutes, Cartilage And Bone Tissue, Vascular Grafts And Organs
Pre-Book The Advanced Therapy Medicinal Products Contract Development And Manufacturing Organization (CDMO) Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
Which Emerging Market Trends Are Altering The Advanced Therapy Medicinal Products Contract Development And Manufacturing Organization (CDMO) Industry?
Companies in the advanced therapy medicinal products CDMO market are advancing cell therapy manufacturing services to streamline production and speed up development. For example, in January 2024, Pluristem Therapeutics Inc., an Israel-based biotech company, introduced PluriCDMO, a new division focused on providing cell therapy manufacturing. Their bioreactor system supports 3D cell multiplication and offers scalable production for a range of therapies, ensuring consistent quality and efficient processes.
Who Are the Key Players In The Advanced Therapy Medicinal Products Contract Development And Manufacturing Organization (CDMO) Market?
Major companies operating in the advanced therapy medicinal products contract development and manufacturing organization (CDMO) market are:
• Thermo Fisher Scientific Inc.
• Merck KGaA
• Resonac Corporation
• Lonza Group AG
• Catalent Inc.
• Charles River Laboratories International Inc.
• Recipharm AB
• KBI Biopharma
• Takara Bio Inc.
• Rentschler Biopharma SE
• Ajinomoto Co. Inc.
• ElevateBio LLC
• Fujifilm Diosynth Biotechnologies
• Axplora Group GmbH
• WuXi Advanced Therapies Inc.
• Celonic Group
• Batavia Biosciences B.V.
• BioCentriq
• Cytovance Biologics
• Andelyn Biosciences
• Genezen
• AGC Biologics
• ABL Manufacturing
• Minaris Regenerative Medicine
• Porton Advanced Solutions
What Are The Regional Insights Into The Advanced Therapy Medicinal Products Contract Development And Manufacturing Organization (CDMO) Market?
North America was the largest region in the advanced therapy medicinal product contract development and manufacturing organization (CDMO) market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the advanced therapy medicinal products contract development and manufacturing organization (CDMO) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
